<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136847</url>
  </required_header>
  <id_info>
    <org_study_id>Bellmed003</org_study_id>
    <nct_id>NCT04136847</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Tolerability of the SkinPen on Male and Female Subjects' Dorsal Hands as a Treatment for Signs of Hand Aging</brief_title>
  <official_title>A Single-Center Trial to Evaluate the Efficacy and Tolerability of the SkinPen on Male and Female Subjects' Dorsal Hands as a Treatment for Signs of Hand Aging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellus Medical, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Microneedling is a relatively new, minimally invasive technique originally developed for skin
      rejuvenation. Controlled micro-injury to the dermis via the application of several small
      needles connected to a motorized device stimulates the wound healing process, resulting in
      the formation of new tissue and blood vessels. The SkinPen by Bellus Medical is an
      FDA-cleared microneedling device proven to improve the appearance of acne scars This study
      evaluates the clinical performance of the SkinPen device for the treatment of signs of aging
      on the back of the hand.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SkinPen microneedling treatment of dorsal hand skin This is a single-site, non-randomized,
      non-controlled study designed to follow at least twenty

      three (23) qualified and consenting subjects treated with 4 Skinpen microneedling treatments.
      The sample size determination of this study is based on the recommendations of the sponsor.
      These patients will be treated four times over the dorsum of the hand from the wrist to the
      knuckles each month for four months, followed by two follow-up visits at 1-month and 3-months
      post-treatment. The acute effects of microneedling will be determined by subjective and
      objective analysis using standard and close-up photography. Additionally, the effects of this
      treatment will be analyzed at 1-month and 3-month post-treatment through clinician and
      subject assessments.

      Subjects will be identified from Dr. Jeffrey Kenkel's clinical practice at the University of
      Texas Southwestern Medical Center. Subjects will be numbered sequentially in the order in
      which they qualify for entry into the study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to COVID 19 the Study did not start enrolling
  </why_stopped>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">December 26, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>At least twenty three (23) qualified and consenting subjects treated with 4 Skinpen microneedling treatments.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aesthetic Assessment of change</measure>
    <time_frame>6 months</time_frame>
    <description>Clinician's global aesthetic improvement assessment (CGAIS) , a 5 point grading scale where 1 is ''Very Much Improved'' and 5 is ''Worse''</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aesthetic Assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Subject's global aesthetic improvement assessment (CGAIS) , a 5 point grading scale where 1 is ''Very Much Improved'' and 5 is ''Worse''</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Monitoring of adverse events throughout the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin density</measure>
    <time_frame>6 months</time_frame>
    <description>Ultrasound Imaging System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Firmness</measure>
    <time_frame>6 months</time_frame>
    <description>BTC 2000</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments of aging signs</measure>
    <time_frame>6 months</time_frame>
    <description>Measurements acquired by the VISIA Complexion Analysis System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Patient Satisfaction Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Hand Aging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microneedling treatment of the dorsum of the hands</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SkinPen Precision</intervention_name>
    <description>Surgical instrument motors and accessories/attachments/Hydrogel</description>
    <arm_group_label>Hand Aging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women 50 to 75 years of age having general good health.

          2. Individuals deemed by the Investigator, visually, to have signs of hand aging
             (presence of skin laxity, age spots, trophic changes) on the dorsum of the hand..
             Also, Subjects would have to be willing to undergo correction of these signs of aging.

          3. Individuals willing to withhold aesthetic therapies to the areas of the hand being
             treated or judged to potentially impact results by the Investigator (e.g. soft tissue
             fillers and/or any resurfacing procedures, botulinum toxin, injectable fillers,
             microdermabrasion, IPL (intense pulsed light), peels, laser treatments, and tightening
             treatments, etc.) for the duration of the study. Waxing and threading is allowed but
             not laser hair removal.

          4. Individuals that are willing to provide written informed consent

          5. Individuals willing to sign a photography release.

          6. Willingness to cooperate and participate by following study requirements for the
             duration of the study and to report any changes in health status or medications,
             adverse event symptoms, or reactions immediately.

          7. Women of child bearing potential agree to take a urine pregnancy test at the Baseline
             visit and 3-months post-treatment or when deemed by Investigator and/or Sponsor. This
             may be changed to a monthly pregnancy test at the Sponsor's discretion. Women who are
             of childbearing potential must have a negative urine pregnancy test result and must
             not be lactating at the baseline visit. Women must be willing and able to use an
             acceptable method of birth control (e.g. barrier methods used with a spermicidal
             agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study.
             Women will not be considered of childbearing potential if one of the following
             conditions is documented on the medical history:

               -  Postmenopausal for at least 12 months prior to study;

               -  Without a uterus and/or both ovaries;

               -  Bilateral tubal ligation at least 6 months prior to study enrollment.

        Exclusion Criteria:

          1. Individuals diagnosed with known allergies to general skin care products.

          2. Individuals who have presence of an active systemic or local skin disease that may
             affect wound healing.

          3. Individuals who have severe solar elastosis.

          4. Individuals with sensitivity to topical lidocaine.

          5. Individuals who have physical or psychological conditions unacceptable to the
             Investigator.

          6. Individuals who have a recent history of significant trauma to the areas to be treated
             (&lt; 6 months).

          7. Individuals who have significant scarring in the area(s) to be treated.

          8. Individuals who have a recent or current history of inflammatory skin disease,
             infection or unhealed wound.

          9. Individuals who have a history of systemic granulomatous diseases, active or inactive,
             (e.g. Sarcoid, Wegeners, TB, etc.) or connective tissue diseases (e.g. lupus,
             dermatomyositis, etc.).

         10. Individuals who currently have or have a history of hypertrophic scars, or keloid
             scars.

         11. Individuals who currently have cancerous or pre-cancerous lesions in the areas to be
             treated and/or with a history of skin cancer.

         12. Individuals who have the inability to understand instructions or to give informed
             consent.

         13. Individuals who have had microdermabrasion or glycolic acid treatment to the treatment
             area(s) within one month prior to study participation or who will have this treatment
             during the study.

         14. Individuals who have a history of chronic drug or alcohol abuse.

         15. Individuals undergoing concurrent therapy that, in the Investigator's opinion, would
             interfere with the evaluation of the safety or efficacy of the study device.

         16. Individuals who, in the Investigator's opinion, have a history of poor cooperation,
             noncompliance with medical treatment, or unreliability.

         17. Individuals who are current smokers or have smoked in the last five years.

         18. Individuals who have a history of the following cosmetic treatments in the area(s) to
             be treated:

               -  Skin tightening procedure within the past year;

               -  Injectable filler of any type within the past:

                    -  12 months for Hyaluronic acid fillers (e.g. Restylane)

                    -  12 months for Ca Hydroxyapatite fillers (e.g. Radiesse)

                    -  24 months for Poly-L-Lactic acid fillers (e.g. Sculptra)

                    -  Ever for permanent fillers (e.g. Silicone, ArteFill)

               -  Neurotoxins within the past three months;

               -  Ablative resurfacing laser treatment;

               -  Non-ablative, rejuvenative laser or light treatment within the past six months;

               -  Surgical dermabrasion;

               -  Had a chemical peel or dermabrasion, of the dorsum of the hand within four weeks

         19. Individuals with a history of using the following prescription medications:

               -  Accutane or other systemic retinoids within the past six months;

               -  Topical Retinoids within the past two weeks;

               -  Prescription strength skin lightening devices (e.g. hydroquinone, tretinoin, AHA,
                  BHA and polyhydroxy acids, 4-hydroxyanisole alone or in combination with
                  tretinoin, etc.) within four months;

               -  Any anti-wrinkle, skin lightening devices, or any other device or topical or
                  systemic medication known to affect skin aging or dyshcromia (devices containing
                  alpha/beta/poly-hydroxy acids, vitamin C, soy, Q-10, hydroquinone; systemic or
                  licorice extract (topically), TegoÂ® Cosmo C250, gigawhite, lemon juice extract
                  (topically), emblica extract, etc.) within two weeks;

               -  Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix, chronic NSAID
                  use); and/or

               -  Psychiatric drugs that in the Investigator's opinion would impair the subject
                  from understanding the protocol requirements or understanding and signing the
                  informed consent.

         20. Individuals who are nursing, pregnant, or planning to become pregnant during the study
             according to subject self-report.

         21. Individuals having a health condition and/or pre-existing or dormant dermatologic
             disease on the body (e.g., psoriasis, rosacea, eczema, seborrheic dermatitis,
             vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory
             hyperpigmentation) that the Investigator or designee deems inappropriate for
             participation or could interfere with the outcome of the study.

         22. Individuals with a history of immunosuppression/immune deficiency disorders (including
             HIV infection or AIDS) or currently using immunosuppressive medications (e.g.,
             azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate
             mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined
             by study documentation.

         23. Individuals with an uncontrolled disease such as asthma, diabetes, hyperthyroidism,
             medically significant hypertension or hypothyroidism. Individuals having multiple
             health conditions may be excluded from participation even if the conditions are
             controlled by diet, medication, etc.

         24. Individuals with any planned surgeries, overnight hospitalization, and/or invasive
             medical procedures during the course of the study.

         25. Individuals who have observable suntan, nevi, excessive hair, etc. or other dermal
             conditions on the back of the hand that might influence the test results in the
             opinion of the Investigator or designee.

         26. Individuals who have any condition, which in the opinion of the Investigator makes the
             patient unable to complete the study per protocol (e.g. patients not likely to avoid
             other cosmetic treatments to the treatment area; patients not likely to stay in the
             study for its duration because of other commitments, concomitant conditions, or past
             history; patients anticipated to be unreliable, or patients who have a concomitant
             condition that may develop symptoms that might confuse or confound study treatments or
             assessments).

         27. Individuals who started hormone replacement therapies (HRT) or hormones for birth
             control less than three months prior to study entry or who plan on starting, stopping,
             or changing doses of HRT or hormones for birth control during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Kenkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTSW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Signs of Hand Aging</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

